PRAME: This study is evaluating how safe and effective a new type of immunotherapy is in people with advanced or metastatic solid cancers that are PRAME positivePhase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers

Exclusion

1. Symptomatic or untreated central nervous system metastasis
2. Recent bowel obstruction
3. Ascites requiring recurrent paracentesis
4. Significant immune-mediated adverse event with prior immunotherapy (patients in checkpoint inhibitor combination treatment)
5. Inadequate washout from prior anticancer therapy
6. Significant ongoing toxicity from prior anticancer treatment
7. Out-of-range laboratory values
8. Clinically significant lung, heart, or autoimmune disease
9. Ongoing requirement for immunosuppressive treatment
10. Prior solid organ or bone marrow transplant
11. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
12. Known history of human immunodeficiency virus (HIV)
13. Significant secondary malignancy
14. Hypersensitivity to study drug or excipients
15. Antibiotics, vaccines or surgery within 2-4 weeks prior to the first dose of study intervention
16. Pregnant or lactating
17. Any other contraindication for applicable combination partner based on local prescribing information